InVisionFirst®-Lung is an NGS-based liquid biopsy test that detects actionable genes relevant to the treatment and management of advanced non-small cell lung cancer (NSCLC)
Challenges we face with testing tumor tissue in advanced NSCLC
- Approximately 80% of NSCLC patients do not have adequate tumor specimen for complete tissue genotyping for all eight guideline-recommended biomarkers.1
- ~1 in 2 patients with advanced or metastatic NSCLC may be eligible for a targeted therapy.2
- Turn-around time for tissue specimen collection-to-analysis is usually longer than for liquid biopsy testing and may not be the optimal approach for all patients.1
InVisionFirst®-Lung is F.A.S.T. approach to biomarker testing
Focused approach tailored for advanced NSCLC patients
Actionable results to inform patient management
Sensitive & Specific to accurately identify tumor mutations found at very low levels in blood
Timely results delivered within 7 days*
“My liquid biopsy test has potentially bought me several more years that I wouldn’t have had otherwise. That’s something that money can’t buy.”
Sasha was a warrior and fought to make the world around her a better place, Sasha lost her battle with Lung Cancer in 2021. At NeoGenomics, we are extremely grateful to Sasha and her family for sharing the journey with us as we continue to focus on improving outcomes for patients daily.
Now Offering Site Location & Mobile Phlebotomy Services
Providers: Fax or email an order to the patient advocate team at Fax: 239.690.4237, email email@example.com to order site location or mobile phlebotomy services.
Patients: call the patient advocate team at 866.776.5907 ext. 9 or email us at firstname.lastname@example.org to schedule a site location testing appointment or in-home blood draw today.
When results from EGFR single nucleotide variants (SNVs) and insertion and deletions (indels); rearrangements in ALK, NTRK1, RET and ROS1; and SNVs for BRAF are not available
When tissue-based CGP is infeasible (i.e. quantity not sufficient (QNS) for tissue-based CGP or invasive biopsy is medically contraindicated).
For patients progressing on or after chemotherapy or immunotherapy who have not been tested for EGFR SNVs and indels; rearrangements in ALK, NTRK1, RET and ROS1; and SNVs for BRAFs, and for whom tissue-based CGP is infeasible;
For patients progressing on EGFR tyrosine kinase inhibitors (TKIs).
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients